Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Manali explains glofitamab binds the same CD20 epitope as obinutuzumab and had high CRS, so the label requires obinutuzumab seven days before the first step-up. Mosunetuzumab shares rituximab's epitope, meaning a mosunetuzumab-rituximab combination would compete for the same binding domain. That mechanistic detail shapes regimen design.

Related Insights

The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.

When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.

Jennifer shows CRS timing differs by drug: glofitamab peaks at the first 2.5 mg step-up, epcoritamab at its first full dose, and mosunetuzumab at the third dose. Follicular lymphoma's extra epcoritamab step-up lowered high-grade CRS. Outpatient monitoring must match the exact agent and dose in practice.

Pre-clearing disease burden with acalabrutinib and venetoclax enables bone marrow recovery prior to introducing obinutuzumab. This delayed addition strategy noticeably improves safety, leading to fewer severe infusion reactions, reduced myelosuppression, and lower potential infection risks compared to early triplet dosing.

Not all CD20-targeting bispecifics can be combined with rituximab. Mosunetuzumab binds the same epitope, causing competition. However, glofitamab and epcoritamab bind different epitopes, allowing for logical and potentially synergistic combinations with rituximab-based regimens.

Despite a major trial using rituximab in its pirtobrutinib-venetoclax combination, experts note a strong clinical preference for obinutuzumab as the more effective anti-CD20 antibody in CLL. This suggests that in real-world practice, clinicians may substitute obinutuzumab, adapting the trial regimen for perceived superior efficacy.

Clinical trial experience shows that delaying the administration of obinutuzumab in an Acalabrutinib-Venetoclax-Obinutuzumab (AVO) triplet regimen improves patient tolerability. This sequencing strategy allows clinicians to enhance response with the antibody later, if needed, while minimizing upfront side effects.

Initiating acalabrutinib and venetoclax upfront while delaying obinutuzumab effectively debulks tumor load before antibody exposure. This delayed-layering strategy significantly cuts infusion reactions, myelosuppression, and severe infection risk while preserving the deep responses necessary for complex or autoimmune manifestations.

An MD Anderson study showed that delaying the addition of obinutuzumab to an acalabrutinib-venetoclax regimen achieved similar deep remission rates (uMRD) as upfront administration. This sequencing strategy significantly reduced severe neutropenia (52% vs 12%) and infections, making the potent combination safer.

Manali emphasizes that CD20 expression must be reconfirmed by flow cytometry or IHC before any CD20 bispecific, because the drug cannot work without its target. In her case, a patient retained CD20 after CAR T and then received glofitamab, showing prior CAR T does not rule out bispecific therapy.